A SART Data Cost-effectiveness Analysis of Planned Oocyte Cryopreservation Versus In vitro Fertilization with Preimplantation Genetic Testing for Aneuploidy Considering Ideal Family Size
Overview
Authors
Affiliations
Objective: To determine the cost-effectiveness of planned oocyte cryopreservation (OC) as a strategy for delayed childbearing to achieve 1 or 2 live births (LB) compared with in vitro fertilization (IVF) and preimplantation genetic testing for aneuploidy (PGT-A) at advanced reproductive age.
Design: Decision tree model with sensitivity analyses using data from the Society for Assisted Reproductive Technology Clinical Outcome Reporting System and other clinical sources.
Setting: Not applicable.
Patient(s): A data-driven simulated cohort of patients desiring delayed childbearing with an ideal family size of 1 or 2 LB.
Intervention(s): Not applicable.
Main Outcome Measure(s): Probability of achieving ≥1 or 2 LB, average and maximum cost per patient, cost per percentage point increase in chance of LB, and population-level cost/LB.
Result(s): For those desiring 1 LB, planned OC at age 33 with warming at age 43 decreased the average total cost per patient from $62,308 to $30,333 and increased the likelihood of LB from 50% to 73% when compared with no OC with up to 3 cycles of IVF/PGT-A at age 43. For those desiring 2 LB, 2 cycles of OC at age 33 and warming at age 40 yielded the lowest cost per patient and highest likelihood of achieving 2 LB ($51,250 and 77%, respectively) when compared withpursuing only 1 cycle of OC ($75,373 and 61%, respectively), no OC and IVF/PGT-A with embryo banking ($79,728 and 48%, respectively), or no OC and IVF/PGT-A without embryo banking ($79,057 and 19%, respectively). Sensitivity analyses showed that OC remained cost-effective across a wide range of ages at cryopreservation. For 1 LB, OC achieved the highest likelihood of success when pursued before age 32 and remained more effective than IVF/PGT-A when pursued before age 39, and for 2 LB, 2 cycles of OC achieved the highest likelihood of success when pursued before age 31 and remained more effective than IVF/PGT-A when pursued before age 39.
Conclusion(s): Among patients planning to postpone childbearing, OC is cost-effective and increases the odds of achieving 1 or 2 LB when compared with IVF/PGT-A at a more advanced reproductive age.
Adamyan L, Pivazyan L, Obosyan L, Krylova E, Isaeva S Obstet Gynecol Sci. 2024; 67(4):356-379.
PMID: 38803301 PMC: 11266849. DOI: 10.5468/ogs.24028.
Ranit H, Shmuel H, Ahlad A, Shirley G, Meny H, Tal I J Assist Reprod Genet. 2024; 41(6):1531-1538.
PMID: 38492156 PMC: 11224053. DOI: 10.1007/s10815-024-03083-z.
Examining reasons that patients discard cryopreserved oocytes.
Namath A, Jahandideh S, Devine K, Kallen C, OBrien J J Assist Reprod Genet. 2023; 40(12):2865-2870.
PMID: 37796420 PMC: 10656384. DOI: 10.1007/s10815-023-02962-1.
Preimplantation genetic testing for sickle cell disease: a cost-effectiveness analysis.
Combs J, Dougherty M, Yamasaki M, DeCherney A, Devine K, Hill M F S Rep. 2023; 4(3):300-307.
PMID: 37719105 PMC: 10504548. DOI: 10.1016/j.xfre.2023.06.001.
Childbearing, Infertility, and Career Trajectories Among Women in Medicine.
Bakkensen J, Smith K, Cheung E, Moreno P, Goldman K, Lawson A JAMA Netw Open. 2023; 6(7):e2326192.
PMID: 37498595 PMC: 10375303. DOI: 10.1001/jamanetworkopen.2023.26192.